ADC Therapeutics Q2 FY26 net loss narrows 70.75% to $16.6 million; revenue rises 2.99% to $19.25 million - ADCT News | RalliesADC Therapeutics Q2 FY26 net loss narrows 70.75% to $16.6 million; revenue rises 2.99% to $19.25 million
A
ADCT• Q2 financial results
- ADC Therapeutics posted Q2 GAAP net loss of USD 16.6 million, narrowing from USD 56.6 million a year earlier.
- Total revenue rose 2.17% year over year to USD 19.25 million, driven by net product revenue of USD 18.6 million.
- Operating loss improved to USD 25.41 million from USD 44.15 million, as total operating expenses fell 29% to USD 44.66 million.
- Cash and cash equivalents totaled USD 219.1 million at June 30, 2026; expected cash runway at least into 2028.
Clinical and regulatory update
- FDA raised benefit-risk concerns on LOTIS-5.
- Enrollment was completed in LOTIS-7, with Phase 3 planning assessed for ZYNLONTA-glofitamab.
